The altered gut microbiota in adults with cystic fibrosis

Show simple item record

dc.contributor.author Fouhy, Fiona
dc.contributor.author Burke, Daniel G.
dc.contributor.author Harrison, M. J.
dc.contributor.author Rea, Mary C.
dc.contributor.author Cotter, Paul D.
dc.contributor.author O'Sullivan, Orla
dc.contributor.author Stanton, Catherine
dc.contributor.author Hill, Colin
dc.contributor.author Shanahan, Fergus
dc.contributor.author Plant, Barry J.
dc.contributor.author Ross, R. Paul
dc.date.accessioned 2017-04-11T13:31:38Z
dc.date.available 2017-04-11T13:31:38Z
dc.date.issued 2017-03-09
dc.identifier.citation Burke, D. G., Fouhy, F., Harrison, M. J., Rea, M. C., Cotter, P. D., O’Sullivan, O., Stanton, C., Hill, C., Shanahan, F., Plant, B. J. and Ross, R. P. (2017) 'The altered gut microbiota in adults with cystic fibrosis', BMC Microbiology, 17(1), pp. 58. doi:10.1186/s12866-017-0968-8 en
dc.identifier.volume 17 en
dc.identifier.issued 1 en
dc.identifier.startpage 58-1 en
dc.identifier.endpage 58-11 en
dc.identifier.issn 1471-2180
dc.identifier.uri http://hdl.handle.net/10468/3873
dc.identifier.doi 10.1186/s12866-017-0968-8
dc.description.abstract Background: Cystic Fibrosis (CF) is an autosomal recessive disease that affects the function of a number of organs, principally the lungs, but also the gastrointestinal tract. The manifestations of cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction in the gastrointestinal tract, as well as frequent antibiotic exposure, undoubtedly disrupts the gut microbiota. To analyse the effects of CF and its management on the microbiome, we compared the gut microbiota of 43 individuals with CF during a period of stability, to that of 69 non-CF controls using 454-pyrosequencing of the 16S rRNA gene. The impact of clinical parameters, including antibiotic therapy, on the results was also assessed. Results: The CF-associated microbiome had reduced microbial diversity, an increase in Firmicutes and a reduction in Bacteroidetes compared to the non-CF controls. While the greatest number of differences in taxonomic abundances of the intestinal microbiota was observed between individuals with CF and the healthy controls, gut microbiota differences were also reported between people with CF when grouped by clinical parameters including % predicted FEV1 (measure of lung dysfunction) and the number of intravenous (IV) antibiotic courses in the previous 12 months. Notably, CF individuals presenting with severe lung dysfunction (% predicted FEV1 ≤ 40%) had significantly (p < 0.05) reduced gut microbiota diversity relative to those presenting with mild or moderate dysfunction. A significant negative correlation (−0.383, Simpson’s Diversity Index) was also observed between the number of IV antibiotic courses and gut microbiota diversity. Conclusions: This is one of the largest single-centre studies on gut microbiota in stable adults with CF and demonstrates the significantly altered gut microbiota, including reduced microbial diversity seen in CF patients compared to healthy controls. The data show the impact that CF and it's management have on gut microbiota, presenting the opportunity to develop CF specific probiotics to minimise microbiota alterations. en
dc.description.sponsorship Science Foundation of Ireland (SFI-CSET grant 02/CE/B124) en
dc.format.mimetype application/pdf en
dc.language.iso en en
dc.publisher BioMed Central en
dc.rights © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. en
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ en
dc.subject Cystic fibrosis en
dc.subject Gut microbiota en
dc.subject 454-pyrosequencing en
dc.subject Microbial diversity en
dc.subject Antibiotic therapy en
dc.title The altered gut microbiota in adults with cystic fibrosis en
dc.type Article (peer-reviewed) en
dc.internal.authorcontactother Paul Ross, College Of Sefs Office, University College Cork, Cork, Ireland. +353-21-490-3000 Email: p.ross@ucc.ie en
dc.internal.availability Full text available en
dc.date.updated 2017-04-11T13:20:59Z
dc.description.version Published Version en
dc.internal.rssid 390799339
dc.contributor.funder Science Foundation Ireland en
dc.contributor.funder Seventh Framework Programme en
dc.contributor.funder European Commission en
dc.description.status Peer reviewed en
dc.identifier.journaltitle BMC Microbiology en
dc.internal.copyrightchecked No !!CORA!! en
dc.internal.licenseacceptance Yes en
dc.internal.IRISemailaddress p.ross@ucc.ie en
dc.identifier.articleid 58
dc.relation.project info:eu-repo/grantAgreement/EC/FP7::SP1::HEALTH/603038/EU/Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified./CFMATTERS en


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Except where otherwise noted, this item's license is described as © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
This website uses cookies. By using this website, you consent to the use of cookies in accordance with the UCC Privacy and Cookies Statement. For more information about cookies and how you can disable them, visit our Privacy and Cookies statement